FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP)

UIVIB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									

hours per response:

0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						. ,				ompany Act								
1. Name and Address of Reporting Person*					2. Issuer Name and Ticker or Trading Symbol								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
COLONNESE MARK P			4	Aviragen Therapeutics, Inc. [AVIR]								Director			10% Ow	ner		
				— L								Officer (give title		Other (sp	ecify		
(Last)	(First)	(Middle)		3. Date of Earliest Transaction (Month/Day/Year)								below) below) Chief Financial Officer					
2500 NORTHWINDS PARKWAY					04/03/2017							Chief Financial Officer						
STE 100																		
				[4	4. If Amendment, Date of Original Filed (Month/Day/Year)							dividual or Jo	oint/Group	Filing	(Check Appl	cable		
(Street)												- 1	Line)					
ALPHA	RETTA (GA	30009										Form filed by One Reporting Person Form filed by More than One Reporting					
,													Form fill Person	ed by More	e tnan	One Reporti	ng	
(City)	(State)	(Zip)															
		Ta	able I - Non-	Derivat	ive S	ecuritie	s A	cquired	, Di	sposed o	f, or Be	neficially	Owned					
Date				2. Transact Date Month/Day	Execution Dat		n Date	Code (Instr.			ed (A) or tr. 3, 4 and 5	Beneficial Owned Fo	Form lly (D) o ollowing (I) (In		Direct Ir Indirect B str. 4) C	7. Nature of ndirect Beneficial Ownership		
								Code	v	Amount	(A) or (D)	Price	Reported Transaction (Instr. 3 and	on(s)		"	nstr. 4)	
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	Code (Instr. Securities		re s I (A) sed str.	6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)			ies g Security	8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	(A)	(D)	Date Exercisal	ole	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	лі(э)			
Stock Option (Right to Buy)	\$0.656	04/03/2017		A		400,000		10/03/201	1 ^{7⁽¹⁾}	04/03/2027	Common Stock	400,000	\$0.656	775,00	00	D		

Explanation of Responses:

1. This stock option vests as follows: 33% of the total stock option vests six (6) months after the grant date, on October 3, 2017 and the remainder of the stock option vests in equal monthly installments beginning November 3, 2017 to April 3, 2018.

/s/ Mark P Colonnese

04/05/2017

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.